Guggenheim lowered the firm’s price target on Eli Lilly (LLY) to $928 from $973 and keeps a Buy rating on the shares. The firm is updating its model ahead of Q1 earnings due to be reported May 1. The tirzepatide franchise remains top of mind and the current prescription trajectory suggests the firm’s and consensus 2025 numbers are “comfortably achievable,” the analyst tells investors in a preview.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Affirm, Grab, Viking, Pfizer, Eli Lilly: Trending by Analysts
- Novartis Stock (NVS) Looks Healthier as it Spends $23B on Ramping Up U.S. Manufacturing
- Morning Movers: Pharmaceuticals sink as impending tariffs seen coming
- Eli Lilly price target lowered to $1,124 from $1,146 at Morgan Stanley
- Trump-Powered Medicare Setback Adds Bullish Impetus for Eli Lilly & Co (LLY) Stock